Endo Pharmaceuticals Reports First Quarter Financial Results

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DUBLIN, May 01, 2014 (PR Newswire Europe via COMTEX) -- Total quarterly revenues of $595 million, reported diluted (GAAP) loss per share of $3.41 and adjusted diluted EPS of $0.92. -- Company raises expected 2014 revenues to a range from $2.55 billion to $2.64 billion and raises expected 2014 adjusted diluted EPS to a range from $3.60 to $3.85. -- Company expects 2014 reported diluted (GAAP) loss per share to be in the range from $1.35 to $1.10. --

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC